Tilray Medical has commercially launched its first medical cannabis product, Tilray Oral Solution CBD100, in Panama through Farmacias Arrocha. This launch marks a key step in expanding patient access to regulated, pharmaceutical-grade medical cannabis in Latin America. The product is manufactured in Portugal under strict EU-GMP standards and supports Panama's emerging medical cannabis framework. Tilray Medical aims to broaden access across over 20 countries, advancing patient care and regulatory compliance in global markets.
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
Tilray Inc reported a record first-quarter revenue of $257.1 million, up 23% year-over-year, fueled by strong growth in its beverage segment and international markets. Beverage revenue surged 82% to $101.5 million, boosted by the BrewDog acquisition,...
Tilray Brands reported a first-quarter revenue record, rising 23% year-over-year, driven by gains in its beer and distribution segments following the BrewDog acquisition. However, its core cannabis sales declined, falling to $56.1 million, causing in...
Tilray Brands reported a record first-quarter fiscal 2027 revenue of $257 million, a 23% increase year-over-year, with gross profit rising 35% to $77.5 million and gross margin expanding to 30%. Growth was led by the beverage segment, which surged 82...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
